Agent 7 — Day Trader — decide: skip
EW is up 1.78% today, a modest but real intraday move suggesting some directional conviction. There are no headlines to attribute the move to, which is neutral — absence of news doesn't disqualify momentum. With 315 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend. However, several factors temper enthusiasm: (1) The move is below the 2-5% threshold that would constitute strong conviction flow — at 1.78%, it's meaningful but not emphatic. (2) The macro context shows T10Y2Y at 1.9σ below trend, a flattening/slightly inverted curve environment that favors defensives broadly, but EW (Edwards Lifesciences) is a medical device company that is somewhat rate-agnostic and not directly in the sectors most reactive to this yield signal. (3) No news catalyst means we can't confirm whether institutional flow is driving this or if it's noise. (4) EW is a mid-cap medical device name — without a sector tailwind or clear catalyst, pure momentum plays in this name can fade. Overall, a slight lean toward continuation given time remaining and the system's asymmetric risk profile (tight stops, defined profit target), but confidence is low.
Agent 7 — Day Trader — day_trade_skipped
EW is up 1.78% today, a modest but real intraday move suggesting some directional conviction. There are no headlines to attribute the move to, which is neutral — absence of news doesn't disqualify momentum. With 315 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend. However, several factors temper enthusiasm: (1) The move is below the 2-5% threshold that would constitute strong conviction flow — at 1.78%, it's meaningful but not emphatic. (2) The macro context shows T10Y2Y at 1.9σ below trend, a flattening/slightly inverted curve environment that favors defensives broadly, but EW (Edwards Lifesciences) is a medical device company that is somewhat rate-agnostic and not directly in the sectors most reactive to this yield signal. (3) No news catalyst means we can't confirm whether institutional flow is driving this or if it's noise. (4) EW is a mid-cap medical device name — without a sector tailwind or clear catalyst, pure momentum plays in this name can fade. Overall, a slight lean toward continuation given time remaining and the system's asymmetric risk profile (tight stops, defined profit target), but confidence is low.
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distribution story. From 2026-08-14 through 2026-09-04, EW oscillated in a tight $89.78–$92.28 cluster on routine volume (ADV-range 1.8M–3.1M), with no meaningful accumulation — up-day volumes (e.g., 2026-08-19 at 3.4M, 2026-08-31 at 4.0M) were not persistently dominant over down-day volumes. Then the path broke DOWN rather than up: 2026-09-08 saw a -3.54% plunge on elevated volume of 3.6M, followed by continued weakness to $86.18 on 2026-09-09 and a failed 1-day bounce to $86.77 on low volume (2.3M) on 2026-09-10. Today, 2026-09-11, the path extended lower to $84.37 on 3.8M (a volume z-score of 2.08 vs. the 20d mean), confirming that down-day volume is expanding as price breaks to new multi-week lows — the hallmark SIR distribution signature of a path drifting down-and-right. Risks: A swift reclaim of the $86–$87 breakdown zone on volume meaningfully below the 20d ADV (signaling seller exhaustion) would invalidate the distribution read and suggest a false breakdown. Additionally, if the macro yield-curve signal (T10Y2Y at 0.33, 1.9σ below trend) reverses sharply toward steepening, Health Care defensives like EW could see a rotation bid that overrides the technical pattern.
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distributive story. From 2026-08-14 through 2026-09-04, price was tightly clustered in the $89.78–$92.28 band on unremarkable volume (ADV ~2.5–2.8M), but the path never pushed meaningfully higher despite several up-days — accumulation was absent. The breakdown leg began on 2026-09-08 with a -3.54% down-day on 3.6M shares (1.33× ADV), followed by today, 2026-09-11, posting -2.77% on 3.8M (1.41× ADV, z-score +2.08) — the two largest-volume sessions in the window are both heavy down-days, driving the path sharply down-and-left from the prior cluster to a new 20-day closing low of $84.37. Up-day volume throughout the window was consistently sub-ADV (e.g., 2.0M on 2026-08-28, 2.3M on 2026-09-10), while down-day volume repeatedly exceeded ADV — the textbook SIR signature of sellers in control under the surface. Risks: A reclaim of the prior $89–$90 cluster zone on volume above 3.5M would invalidate the distributive read and suggest the break was a shakeout rather than genuine supply. Additionally, macro tailwinds — such as a sharp steepening of the T10Y2Y yield curve back toward trend — could lift Health Care defensives broadly and overwhelm the stock-specific technical damage.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 4 — Dip Buyer (Frozen) — decide: buy
The 10.2% drawdown from the 30-day high appears technically driven rather than fundamentally justified — there is no negative company-specific news, no guidance cut, and no deterioration signal in the SEC filings. On the contrary, a significant positive catalyst emerged: CMS expanded TAVR Medicare coverage to asymptomatic patients (2026-09-11), which is a direct tailwind for Edwards Lifesciences' core structural heart business. BTIG reiterates a Buy with a $110 price target (representing ~30% upside from current levels), reinforcing the constructive fundamental view.
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path reveals a textbook distribution arc: EW spent the bulk of August through early September clustered in a tight $89.78–$92.28 band on routine volume (ADV near 2.7M), then broke decisively lower on the three largest-volume sessions of the entire window. The initial breakdown came on 2026-09-08 (close $86.72, volume 3.6M, -3.54%), followed by today's 2026-09-11 close of $84.37 on 3.8M shares — a volume z-score of 2.08 — extending the slide to a new 20-day low. Critically, the up-days throughout the path (e.g., 2026-08-31 at 4.0M was the lone high-volume up-day, yet price only gained +0.60%) were unable to generate sustained rightward-upward momentum, while the two sharpest down-days arrived on the highest volume, a classic down-and-right distributional drift under the SIR framework. Risks: The macro context flags a 5-year inflation breakeven (T5YIFR) running 1.8σ above its 24-month trend, adding a rate-sensitive headwind to Health Care broadly; a reversal back above $86.77 (the 2026-09-10 close) on shrinking volume would challenge the distribution read and could signal a bear trap rather than genuine selling pressure.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 7 — Day Trader — decide: skip
With only 5 minutes remaining until the forced close, there is virtually no time for meaningful continuation even if the setup were compelling. The -2.57% move is significant and represents real selling pressure, but at this stage the trade is essentially over regardless of direction. The macro context (elevated 5Y5Y inflation forward rate 1.8σ above trend) is mildly negative for rate-sensitive equities like EW, which provides some directional support, but this cannot overcome the time constraint. With 5 minutes left, the risk/reward of chasing a down move is poor — the +3% profit target is unreachable in this window, and any remaining move is likely noise or end-of-day positioning rather than continuation flow. Probability falls well below 0.5 solely due to time exhaustion.
Agent 7 — Day Trader — day_trade_skipped
With only 5 minutes remaining until the forced close, there is virtually no time for meaningful continuation even if the setup were compelling. The -2.57% move is significant and represents real selling pressure, but at this stage the trade is essentially over regardless of direction. The macro context (elevated 5Y5Y inflation forward rate 1.8σ above trend) is mildly negative for rate-sensitive equities like EW, which provides some directional support, but this cannot overcome the time constraint. With 5 minutes left, the risk/reward of chasing a down move is poor — the +3% profit target is unreachable in this window, and any remaining move is likely noise or end-of-day positioning rather than continuation flow. Probability falls well below 0.5 solely due to time exhaustion.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Top S&P500 movers in Friday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Stay informed with the top movers within the S&P500 index on Friday.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.
Agent 5 — Dip Buyer (Evolving) — decide: skip
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 5 — Dip Buyer (Evolving) — dip_skipped
EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.
Agent 7 — Day Trader — decide: skip
EW is down 1.80% today following a headline about a TAVR National Coverage Decision comment, which is directly relevant to Edwards Lifesciences as TAVR (transcatheter aortic valve replacement) is their core product line. Coverage decisions can meaningfully impact revenue expectations, and the market appears to be pricing in some concern. The move is real but not extreme (~1.8%), suggesting initial reaction rather than exhaustion. With 310 minutes remaining (essentially a full remaining session), there is ample time for continuation. The macro backdrop — elevated 5-year forward inflation rates at 1.8σ above trend — creates mild headwinds for rate-sensitive med-tech names like EW, adding a soft tailwind to the downside thesis. However, the move size is modest, and without clear confirmation of a negative CMS ruling (the headline says 'comments on' rather than 'denies'), there is uncertainty about whether the worst is priced in or if further selling follows as analysts digest the implications. No strong reversal signals are evident. Overall, modest continuation bias to the downside with limited conviction — probability sits at 0.54.
Agent 7 — Day Trader — day_trade_skipped
EW is down 1.80% today following a headline about a TAVR National Coverage Decision comment, which is directly relevant to Edwards Lifesciences as TAVR (transcatheter aortic valve replacement) is their core product line. Coverage decisions can meaningfully impact revenue expectations, and the market appears to be pricing in some concern. The move is real but not extreme (~1.8%), suggesting initial reaction rather than exhaustion. With 310 minutes remaining (essentially a full remaining session), there is ample time for continuation. The macro backdrop — elevated 5-year forward inflation rates at 1.8σ above trend — creates mild headwinds for rate-sensitive med-tech names like EW, adding a soft tailwind to the downside thesis. However, the move size is modest, and without clear confirmation of a negative CMS ruling (the headline says 'comments on' rather than 'denies'), there is uncertainty about whether the worst is priced in or if further selling follows as analysts digest the implications. No strong reversal signals are evident. Overall, modest continuation bias to the downside with limited conviction — probability sits at 0.54.
CMS expands TAVR Medicare coverage to asymptomatic patients
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target
BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.
Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):
Agent 7 — Day Trader — decide: skip
EW is down 3.58% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation. The move is meaningful in magnitude and reflects real flow conviction. Macro context shows the 5-year forward inflation rate (T5YIFR) elevated at 1.7σ above trend, which pressures rate-sensitive sectors and medtech/healthcare device names like EW that carry growth premium valuations sensitive to discount rate assumptions. With 205 minutes remaining, there is ample time for continuation but also for mean reversion. No news headline removes a potential catalyst for acceleration but also removes a clear catalyst for reversal. The absence of a bounce so far mid-session (given the move has already occurred) slightly favors continuation over fade — sellers appear to have controlled the tape. However, the lack of any confirmatory news, unclear volume data, and the macro tailwind being modest rather than acute keeps conviction in the moderate range. Assigning a slight lean toward continuation given macro headwind alignment and no reversal signal evident.
Agent 7 — Day Trader — day_trade_skipped
EW is down 3.58% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation. The move is meaningful in magnitude and reflects real flow conviction. Macro context shows the 5-year forward inflation rate (T5YIFR) elevated at 1.7σ above trend, which pressures rate-sensitive sectors and medtech/healthcare device names like EW that carry growth premium valuations sensitive to discount rate assumptions. With 205 minutes remaining, there is ample time for continuation but also for mean reversion. No news headline removes a potential catalyst for acceleration but also removes a clear catalyst for reversal. The absence of a bounce so far mid-session (given the move has already occurred) slightly favors continuation over fade — sellers appear to have controlled the tape. However, the lack of any confirmatory news, unclear volume data, and the macro tailwind being modest rather than acute keeps conviction in the moderate range. Assigning a slight lean toward continuation given macro headwind alignment and no reversal signal evident.
Is Edwards Lifesciences Stock Underperforming the Dow?
Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound
Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif., September 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.
Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences
Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Aristotle Value Equity WM Q2 2026 Portfolio Performance
For the second quarter of 2026, Aristotle Capitalâs Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Read more here.
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Agent 7 — Day Trader — decide: skip
EW is up 2.22% intraday, a meaningful move reflecting real institutional flow. With 355 minutes remaining (essentially a full session still ahead, suggesting this is an early-session read), there is ample time for continuation. No headlines are present, but absence of news does not disqualify momentum — this appears to be flow-driven. The macro context shows T10Y3M at 0.92, elevated 1.8σ above trend, which is constructive for risk assets broadly, though EW (Edwards Lifesciences) as a medical device/healthcare name is not directly in the recession-sensitive or bank sector categories flagged, making the macro factor roughly neutral to mildly supportive. No reversal signal or fade pattern is described. The move is below the 5% threshold where exhaustion becomes a strong concern. Overall, ordinary momentum with no strong countervailing reason to fade gives a modest continuation edge.
Agent 7 — Day Trader — day_trade_skipped
EW is up 2.22% intraday, a meaningful move reflecting real institutional flow. With 355 minutes remaining (essentially a full session still ahead, suggesting this is an early-session read), there is ample time for continuation. No headlines are present, but absence of news does not disqualify momentum — this appears to be flow-driven. The macro context shows T10Y3M at 0.92, elevated 1.8σ above trend, which is constructive for risk assets broadly, though EW (Edwards Lifesciences) as a medical device/healthcare name is not directly in the recession-sensitive or bank sector categories flagged, making the macro factor roughly neutral to mildly supportive. No reversal signal or fade pattern is described. The move is below the 5% threshold where exhaustion becomes a strong concern. Overall, ordinary momentum with no strong countervailing reason to fade gives a modest continuation edge.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.83 cash available; close=$86.07.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $38.17 cash available; close=$85.76.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $38.17 cash available; close=$85.76.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $12.83 cash available; close=$85.78.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.83 cash available; close=$85.78.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $6.90 cash available; close=$83.68.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 7 — Day Trader — decide: skip
EW is up 2.08% intraday with no attributable headline, suggesting organic institutional flow rather than a news-driven pop that might fade quickly. The macro context shows T10YIE at 1.8σ below trend (low inflation expectations), which is modestly supportive for long-duration sensitive sectors and generally benign for healthcare/medtech names like Edwards Lifesciences. With 184 minutes remaining there is ample time for continuation, and the move size (just over 2%) is meaningful but not so extended that a fade is likely already baked in. No reversal signals are noted. The absence of news does not disqualify the setup — it may reflect pre-earnings positioning or sector rotation. Key risks: no catalyst confirmation means the move could stall if buyers are exhausted, and the macro read is indirect for this ticker. Overall this is a modest momentum continuation setup with no strong fade trigger, warranting a probability just above the neutral threshold.
Agent 7 — Day Trader — day_trade_skipped
EW is up 2.08% intraday with no attributable headline, suggesting organic institutional flow rather than a news-driven pop that might fade quickly. The macro context shows T10YIE at 1.8σ below trend (low inflation expectations), which is modestly supportive for long-duration sensitive sectors and generally benign for healthcare/medtech names like Edwards Lifesciences. With 184 minutes remaining there is ample time for continuation, and the move size (just over 2%) is meaningful but not so extended that a fade is likely already baked in. No reversal signals are noted. The absence of news does not disqualify the setup — it may reflect pre-earnings positioning or sector rotation. Key risks: no catalyst confirmation means the move could stall if buyers are exhausted, and the macro read is indirect for this ticker. Overall this is a modest momentum continuation setup with no strong fade trigger, warranting a probability just above the neutral threshold.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $6.90 cash available; close=$83.68.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $6.28 cash available; close=$83.68.
Abbott starts TriClip study amid rising competition for heart valve repair
Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $6.28 cash available; close=$83.68.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $5.71 cash available; close=$83.04.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $5.71 cash available; close=$83.04.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. No hard veto conditions apply — the 8-K filed 2026-07-23 contains no disclosed fundamental deterioration, no earnings are imminent, and the 13.8% drop falls below the 35% extreme-drop veto threshold. Positive signals: no earnings within 30 days (+1), macro context is neutral-to-improving with T10YIE running 1.7σ below trend suggesting disinflation tailwinds for a long-duration medtech name (+1), and EW's TMTT segment is posting 47% revenue growth signaling underlying business momentum (+0.5 qualitative). Negative signals: the 10Y at 4.69% is a structural headwind for a growth-sensitive medtech name (-1), options flow is balanced (P/C 0.88, both call and put volumes near z≈-0.2 to -0.3, no unusual signal, score 0), insider activity is minimal and routine (one small CVP tax/10b5-1-style sale, not clustered, score 0), and the drop is below the 15% threshold so no extra mean-reversion credit is earned. The sector (XLV) showed +3.01pts vs SPY over 5 days, meaning the drop appears idiosyncratic to EW rather than sector-wide (-1). Net: +1, with no fundamental impairment, supporting a marginal buy near the base rate anchor.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
CroíValve Announces the Appointment of Jaime Wheeler as Chief Executive Officer
DUBLIN, July 28, 2026--CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare exe
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $22.47 cash available; close=$83.75.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion?
On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $22.47 cash available; close=$83.75.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Leerink Partners Upgrades Edwards Lifesciences (EW)
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium
Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path is a textbook distribution sequence: EW peaked near $95.18 on 2026-07-06 on modest volume (4.0M), then embarked on a persistent down-and-right drift — every meaningful down-day carried escalating volume (2026-07-09: -2.47% on 5.6M; 2026-07-14: -1.85% on 5.2M; 2026-07-15: -3.13% on 8.2M), while the intermittent up-days were uniformly low-volume (2026-07-10: +0.96% on only 3.4M; 2026-07-16: +0.65% on 6.0M). Today's final bar (2026-07-24: close $82.64, volume 16.1M, z-score +4.29 vs. 20-day ADV of 5.2M) is a climactic 3× ADV down-day that drives the scatter path sharply down-right — the heaviest single session in the entire window occurred on a down-close, confirming sellers remain firmly in control and offering no accumulation signal whatsoever. Risks: A reversal would be signaled if the next 2-3 sessions produce high-volume up-days (>8M) that reclaim the $85–$87 zone — that would recast today's spike as a selling climax rather than continued distribution. Additionally, today's volume extreme could mark a short-term exhaustion low, so a close back above $84 on expanding up-day volume within 1-2 sessions would warrant reassessment.
Friday's session: gap up and gap down stock in the S&P500 index
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Friday. Discover the gap up and gap down stocks in the S&P500 index.
Edwards, The 'Cleanest Large-Cap Medtech Story,' Launches On Second-Quarter Beat
Edwards Lifesciences stock launched higher Friday after the medtech company beat Wall Street's top- and bottom-line expectations.
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
Edwards lifts FY26 growth outlook following steady Q2 performance
Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101
Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
These S&P500 stocks are moving in today's pre-market session
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary
Moby summary of Edwards Lifesciences Corporation's Q2 2026 earnings call
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion
An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Lifesciences, SAP in Focus (UPDATED)
U.S. stock futures were higher on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Thursday's lower close.
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ...
Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.
American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
US stock futures mixed, focus on companies like American Express, Deckers, Verizon, Edwards Lifesciences, and HCA Healthcare for today's trading.
Edwards Lifesciences Q2 Earnings Call Highlights
Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products. Chief Executive Officer Bernard Zovighian said the
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.47 cash available; close=$83.75.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $13.89 cash available; close=$84.37.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Stock Launches As Heart-Valve Replacements Beat On
Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.
Which S&P500 stocks are moving after the closing bell on Thursday?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.
Edwards Lifesciences (NYSE:EW) Raises Guidance After Solid Q2 Earnings, Stock Surges 6%
Edwards Lifesciences reported Q2 2026 earnings in line with estimates, posted $0.78 EPS, and raised full-year sales guidance, driving a 6.2% after-hours stock surge.
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call July 23, 2026 5:00 PM EDTCompany ParticipantsGerianne Sarte - Investor Relations OfficerBernard...
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif., July 23, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est
Edwards Lifesciences (NYSE:EW) is looking for Q3 Adj EPS of $0.71-$0.77 vs $0.74 analyst estimate. sees sales of $1.630 billion-$1.710 billion vs $1.689 billion analyst estimate.
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est
Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion
Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate
Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. This is a 16.42 percent increase over earnings of $0.67 per share from
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $13.89 cash available; close=$84.37.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $13.65 cash available; close=$84.36.
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $13.65 cash available; close=$84.36.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.68 cash available; close=$84.55.
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.68 cash available; close=$84.55.
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.68 cash available; close=$84.55.
Agent 4 — Dip Buyer (Frozen) — decide: skip
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 4 — Dip Buyer (Frozen) — dip_skipped
Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.68 cash available; close=$84.55.
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $15.08 cash available; close=$84.55.
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $6.42 cash available; close=$85.73.
Edwards' Q2 Earnings on the Horizon: What's in the Cards?
EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.
options_momentum closed long 100 @ $2.15 (-$82.39)
Stop: premium $2.15 ≤ trailing floor $2.23 (peak $2.97 × 0.75)
options_momentum opened long 100 @ $2.97
options_momentum closed long 200 @ $2.96 (-$42.38)
Stop: premium $2.96 ≤ trailing floor $2.98 (peak $3.98 × 0.75)
options_momentum opened long 200 @ $3.17